 
 
Dated: 19th November, 2025 
To 
The Manager       The Manager 
Listing Department      Listing Department 
National Stock Exchange of India Limited    BSE Limited 
Exchange Plaza, C-1, Block G,      Phiroze Jeejeebhoy Tower, 
Bandra Kurla Complex, Bandra (E),     Dalal Street    
Mumbai – 400 051       Mumbai-400001 
 
Script Symbol: GODAVARIB     Script Code:544279 
 
Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing 
Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) –
Incorporation of overseas wholly owned step-down subsidiary. 
Pursuant to the compliance with Regulation 30 read with Part A of Schedule III of the Securities 
and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 
2015 (including any statutory modiﬁcation(s), amendment(s) or re-enactment(s) thereof for the 
time being in force), We would like to inform you that the Godavari Bioreﬁneries Inc, Step down 
Subsidiary of the Company has incorporated a overseas wholly owned subsidiary with the name 
of Sathgen Therapeutics, LLC under the law of USA on  17th November, 2025   , 2025. Consequent 
to the incorporation of Sathgen Therapeutics, LLC, it will become a Wholly Owned Step-Down 
Subsidiary of the Company (“SDS-WOS”) 
The details with respect to the said incorporation as required under Regulation 30(6) read with 
Schedule III Part A Para A (1) of the Listing Regulations and SEBI Master Circular No. 
SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 and the SEBI Circular No. 
SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are attached as Annexure -A. 
Kindly take the same on your record and bring notice to all the concerned. 
For Godavari Bioreﬁneries Limited 
 
 
Manoj Jain 
Company Secretary and Compliance Officer 
Membership Numnber-F-7998 
 
 
 
 
The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) 
Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/CFD-PoD- 1/P/CIR/2023/123 dated 
July 13, 2023 and the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 
are given below: 
SN Details to be provided Information 
1 Name of the target entity, details in brief such 
as size, turnover etc 
Name of the Target Company:  
Sathgen Therapeutics, LLC 
 
Share Capital: US$ 350,000 
 
Turnover: Not Applicable 
 
2 Whether the acquisition/ incorporation would 
fall within related party transactions and 
whether the promoter/ promoter group/ group 
companies have any interest in the entity being 
acquired? If yes, nature of the interest and 
details thereof and whether the same is done 
at 'arm's length' 
Not Applicable 
3 Industry to which the entity being acquired/ 
incorporated belongs 
Pharmaceutical marketing.  
4 Objects and impact of acquisition (including 
but not limited to, disclosure of reasons for 
acquisition of target entity, if its business is 
outside the main line of business of the listed 
entity) 
The (“SDS-WOS”) shall inter- alia deal in the 
existing range of business 
5 Brief details of governmental or regulatory 
approvals required for the acquisition/ 
incorporation 
Not Applicable 
6 Indicative time period for completion of the 
acquisition/ incorporation 
Date of Incorporation- 17th November, 2025 
7 Nature of Consideration whether Cash 
consideration or share swap or any other and 
details of the same 
Cash 
8 Cost of Acquisition or the price at which the 
shares are acquired/ subscribed 
The Godavari Biorefineries INC has subscribed 
share capital of Sathgen Therapeutics, LLC 
for amount of US$ 350,000  
 
9 Percentage of shareholding control acquired 
and /or number of shares acquired 
100% 
10 Brief background about the entity acquired in 
terms of products/ line of business acquired, 
date of incorporation, history of last 3 years 
turnover, country in which the acquired entity 
has presence and any other significant 
information (in brief 
Date of incorporation: 17th November, 2025  
Product/line of business: Pharmaceutical 
marketing. (Business development for drugs 
developed by Godavari Biorefineries, Ltd, India 
Last 3 years turnover: NA 
Presence of entity: USA 
